Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Proclara Biosciences
MINIject has been approved in Europe for open-angle glaucoma patients.
The company intends to use the series B cash to bring the first of its pan-amyloid removal (PAR) therapies into the clinic, while also advancing a diagnostic tool for systemic amyloidosis.
iSTAR Medical reported six-month clinical trial data supporting its latest micro-invasive glaucoma surgery device, MINIject.
Appointments: Oculis, PellePharm, Syntimmune, Sterna Biologicals, Proclara Biosciences, Denovo Biopharma and OrphoMed
The latest biopharma industry appointments include new CEOs at Oculis, PellePharm, Syntimmune and Sterna Biologicals and a new CFO at Oculis, as well as new CMOs at Proclara Biosciences, Denovo Biopharma and OrphoMed.
- Large Molecule
- Other Names / Subsidiaries
- NeuroPhage Pharmaceuticals, Inc.
- Proclara Biosciences Australia Pty Ltd